Medication burden, characterized by polypharmacy and suboptimal treatment adherence, is a predictor for acute care use among ...
At the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, Alexa Meara, MD, explored the interface of oncology and rheumatology in the immunotoxicity ...
Izalontamab (SI-B001), a novel EGFR/HER3 bispecific monoclonal antibody, was well-tolerated and exhibited preliminary ...
Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues ...
A positive trend in overall survival was observed, favoring sacituzumab govitecan over chemotherapy, though data is still ...
In an interview with Targeted Oncology at the 2025 North American Neuroendocrine Tumor Society (NANETS) Symposium, Michael ...
The segment concludes that long-term data reinforce the durability and clinical relevance of combination immunotherapy, ...
A panelist discusses how both lurbinectedin and tarlatamab remain important in the management of relapsed small cell lung ...
The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk ...
Jason S. Starr, DO, assistant professor of medicine and a hematologist/oncologist in the Department of Internal Medicine at ...
The FDA accepted the investigational new drug application for UGN-103 in April 2024. These new positive data position the ...
A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management. A panelist discusses how the therapeutic landscape of extensive-stage small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback